| Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. | |
| | |
MedLine Citation:
|
PMID: 16718469 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Ovarian cancer has the highest mortality of all the gynecologic cancers. The antitumor agent paclitaxel has been proved to be efficient in the treatment of ovarian cancer. Our study is to develop a polymeric drug delivery system for paclitaxel and determine whether paclitaxel nanoparticle can inhibit growth of ovarian carcinoma xenografts in Fisher344 (F344) rats by intraperitoneal administration. The mechanism of paclitaxel nanoparticles in rats bearing ovarian cancer has been investigated in this study. METHODS: Synthesize paclitaxel loading nanoparticle (PLA) by ultrasonic emulsification; MTT analysis identified cytotoxic activity of paclitaxel nanoparticle in vitro; rat ovarian carcinoma cells were injected into the peritoneal cavity of F344 rats. The antitumor effect of paclitaxel nanoparticle in vivo has been evaluated by measuring tumor weight and ascite volume. At the end of the procedure rats were sacrificed; tumors were excised and processed for PCNA staining, tissue terminal deoxynucleotide transferase-mediated dUTP nick and labeling assay and RT-PCR to evaluate the proliferative and apoptotic changes and cancer transfer-related gene expression induced by PLA. Paclitaxel concentration in plasma, pelvic lymph nodes, liver, and heart were determined by high-performance liquid chromatography. RESULTS: Paclitaxel nanoparticle and PTX (Cremophor) showed equivalent cytotoxic activity in vitro. In rats implanted carcinoma cells, paclitaxel nanoparticles significantly reduced tumor weight and ascites volume, and induced apoptosis of tumor cells. PLA also inhibited cell proliferation and matrix metalloproteinase 9 mRNA expression. The paclitaxel concentration of pelvic lymph nodes in PLA treated animals was 20-fold higher than that of free PTX treated animals at 48 h after intraperitoneal administration. CONCLUSION: The intraperitoneal administration of paclitaxel nanoparticle can significantly inhibit the progression of ovarian carcinoma in peritoneal cavity of female F344 rat. The paclitaxel nanoparticle is safe and lymphatic targeting. |
| | |
Authors:
|
Hongxia Lu; Bin Li; Yu Kang; Wei Jiang; Qian Huang; Qinghua Chen; Limin Li; Congjian Xu |
Related Documents
:
|
22885549 - Granular cell variant of epithelioid cell histiocytoma. 22784709 - Peptidomimetic src/pretubulin inhibitor kx-01 alone and in combination with paclitaxel ... 22623369 - Targeting the e3 ubiquitin ligase c-cbl decreases osteosarcoma cell growth and survival... 22461519 - Gut microbiota accelerate tumor growth via c-jun and stat3 phosphorylation in apcmin/+ ... 22516549 - Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas. 22330989 - A novel markerless technique to evaluate daily lung tumor motion based on conventional ... 15113479 - Astroglia induce cytotoxic effects on brain tumors via a nitric oxide-dependent pathway... 1540969 - Measurements of blood flow and exchanging water space in breast tumors using positron e... 9635679 - Mdr1 expression is associated with adverse survival in melanoma of the uveal tract. |
Publication Detail:
|
Type: Journal Article Date: 2006-05-23 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 59 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2006-11-30 Completed Date: 2007-04-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 175-81 Citation Subset: IM |
Affiliation:
|
Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents, Phytogenic / administration & dosage, pharmacokinetics, therapeutic use Apoptosis / drug effects Ascites / drug therapy Cell Line, Tumor Cell Proliferation / drug effects* Drug Delivery Systems / methods Female Gene Expression Regulation / drug effects In Situ Nick-End Labeling Lymph Nodes / drug effects, metabolism, pathology Lymphatic Vessels / drug effects, metabolism*, pathology Matrix Metalloproteinase 1 / genetics, metabolism Matrix Metalloproteinase 9 / antagonists & inhibitors, genetics, metabolism Nanoparticles / administration & dosage Ovarian Neoplasms / drug therapy, prevention & control* Paclitaxel / administration & dosage, pharmacokinetics, therapeutic use* Proliferating Cell Nuclear Antigen / metabolism RNA, Messenger / genetics, metabolism Rats Rats, Inbred F344 Reverse Transcriptase Polymerase Chain Reaction / methods Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Proliferating Cell Nuclear Antigen; 0/RNA, Messenger; 33069-62-4/Paclitaxel; EC 3.4.24.35/Matrix Metalloproteinase 9; EC 3.4.24.7/Matrix Metalloproteinase 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of extreme temperatures on daily mortality in Madrid (Spain) among the 45-64 age-group.
Next Document: Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated p...